Hexiris Ophthalmics Advances Glaucoma Care with New Technologies and Digital Launch
Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, Montreal
Image: Benzinga
Hexiris Ophthalmics, a Canadian ophthalmic device firm, is set to launch its innovative glaucoma treatment technologies in 2026. The company will showcase its products at the Canadian Ophthalmological Society Annual Meeting in Montreal, emphasizing the shift towards office-based glaucoma surgeries.
- 01Hexiris Ophthalmics is preparing to launch its first products in 2026, focusing on interventional glaucoma care.
- 02The company will present its technologies at the COS Annual Meeting in Montreal, offering hands-on experiences for surgeons.
- 03An estimated 80 million people globally are affected by glaucoma, with many lacking access to effective treatment.
- 04Office-based glaucoma procedures could significantly improve patient access and reduce costs compared to traditional hospital settings.
- 05Hexiris has launched a new website and social media channels to enhance engagement with surgeons and stakeholders.
Advertisement
In-Article Ad
Hexiris Ophthalmics, based in Dieppe, New Brunswick, is making significant strides towards the commercial launch of its innovative glaucoma treatment technologies, scheduled for later in 2026. The company announced its participation in the Canadian Ophthalmological Society (COS) Annual Meeting in Montreal, Quebec, where it will provide surgeons with hands-on experience of its products, OBi Core and OBi Gon, through a dedicated dry lab session. This initiative aligns with the growing trend of office-based surgeries, which have shown to reduce patient costs by 30 to 50% without compromising safety. With approximately 80 million people worldwide affected by glaucoma, Hexiris aims to address the critical access issues that prevent effective treatment for many patients. The company has also launched a new website and social media presence to better connect with surgeons and stakeholders, emphasizing its commitment to expanding access to interventional glaucoma care. Founded by Dr. Houfar Sekhavat and Dr. Nir Shoham-Hazon, Hexiris is dedicated to simplifying glaucoma treatment through innovative devices, with OBi Core already approved by Health Canada and registered with the FDA.
Advertisement
In-Article Ad
The introduction of office-based glaucoma surgeries by Hexiris could significantly enhance patient access to necessary treatments in Canada and beyond.
Advertisement
In-Article Ad
Reader Poll
What do you think about the shift to office-based glaucoma surgeries?
Connecting to poll...
Read the original article
Visit the source for the complete story.





